BioActor receives EUROSTARS grant for the FlaMeS project “Flavonoids and metabolic syndrome”

Maastricht, The Netherlands, October 22th, 2012

Press release
BioActor leads the international FlaMeS-consortium to develop novel in-vitro cell technology and clinical validation of Cordiart® for the prevention of the metabolic syndrome. The FlaMeS consortium is a collaboration between two innovation driven SMEs, BioActor (Netherlands) and AdipoPhyt (France). The project will result in the development and clinical validation of novel 3-D cell assays for adipose tissue development and in the clinical validation of a proprietary citrus flavonoid extract for the improvement of glycaemic control and endothelial function.

Metabolic Syndrome

The FlaMeS project

BioActor BV announced today that EUREKA has approved the FlaMeS project, submitted by BioActor and AdipoPhYt. The FlaMeS Consortium has two objectives: (1) validating novel 3-D cell-based assays to screen for effects of compounds on adipose tissue development, and (2) clinically test and validate effects of Cordiart®, a citrus peel extract, on markers associated with the metabolic syndrome.

Prevalence of obesity and the metabolic syndrome is rapidly increasing, affecting millions of people in Europe alone. Public health authorities have recognized the need for prevention of these chronic diseases. BioActor addresses this need by developing a unique, natural product for improved functioning of blood vessels, glycemic control and heart health: Cordiart®.

Cordiart® is a natural flavonoid citrus peel extract with optimized bioavailability. This ingredient commands a high content of natural bioactive flavonoids. A number of in-vivo and human studies have shown very promising effects for Cordiart® in use for blood vessel function, glycemic control and heart health.

In order to test novel substances regarding their effects on adipose tissue (fat storage cells), new ‘humanized’ in vitro models are needed. AdipoPhYt is currently developing a cutting edge new technology “AdipoGut”, combining all present techniques and knowledge into a high quality and predictive test system. The FlaMeS project will result in a marketable functional food ingredient “Cordiart®”, with proven beneficial effects on blood flow, glycemic control and heart health and a cutting edge new in vitro screening technology.

“We are very happy with the Eureka/Eurostars commission’s trust in our project, as this clearly shows that they recognize our serious efforts in developing cutting edge food ingredients and food development technology at BioActor and our partner AdipoPhYt. This grant will enable us to further enhance our scientific knowledge on the effects of polyphenols on the human body and validate our product Cordiart®, which may even revolutionize the health market in cardiovascular disease prevention,” says Hans van der Saag, CEO BioActor.

About BioActor

BioActor, based in Maastricht, Netherlands, is a product development company that has developed a range of proprietary bioactive ingredients for the nutrition & healthcare industry. The company focuses on the development of innovative activities that address active living and healthy aging. The goal is to provide the nutrition & healthcare industry with science-based innovations that confer a real health benefit to the consumer.

Feel free to contact us via info@bioactor.com for more information on the possibilities Cordiart® has to offer.
Further information can be found on: www.cordiart.com